(PharmaNewsWire.Com, August 13, 2017 ) Osteoarthritis (OA) constitutes a growing public health burden, and is the most common cause of musculoskeletal disability around the world. Resulting from a complex interaction of biomechanical, biochemical, and genetic factors, OA develops slowly and is characterized by the degradation of the affected joint's cartilage and bone hypertrophy. The disability is accompanied by joint pain, stiffness, and loss of range of motion. Initially treated with various therapies including physical therapy and nonsteroidal anti-inflammatory drugs (NSAIDs) , advanced cases of OA have traditionally been treated surgically. However, intra-articular viscosupplementation with hyaluronic acid (HA) , a high-molecular-weight glycosaminoglycan, has become an increasingly accepted therapeutic alternative to knee replacement surgery in the symptomatic management of OA over the past decade.
This report focuses on the market outlook for viscosupplementation products in North America (Canada, Mexico, and US) . The analysis discusses the major drivers and barriers of adoption, and provides an in-depth understanding of the future outlook for this market by segment and geography. Scope
- Overview of recent key industry events and analysis of their market impact. - Annualized total market revenue by type of device, procedure trends, and market outlooks by segment and by country through 2023. - Key topics covered include strategic competitor assessment, market characterization, and implications of the emerging technologies in the market. - Pipeline analysis: Comprehensive data split across different stages of development, including a discussion of emerging trends and devices in development. - Analysis of the current and future market competition in the North American viscosupplementation market. Insightful review of the key industry drivers, barriers, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The report will enable you to - - Develop and design your in-licensing and out-licensing strategies through a review of marketed products and technologies. - Develop business strategies by understanding the trends shaping and driving the viscosupplementation market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the viscosupplementation market in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track device sales in country-specific viscosupplementation markets from 2014-2023. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Companies Mentioned: Anika Therapeutics Ferring Pharmaceuticals Fidia Farmaceutici Sanofi Seikagaku Corporation Inquire for Report at http://www.reportsweb.com/inquiry&RW0001851116/buying
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: